---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-108952"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2026-09-18T20:30:44+00:00"
generated_at: "2026-09-18T20:31:14.439072+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics sets LYTENAVA US wholesale acquisition cost at $485/vial

## Summary
- On Sep 16, 2026, Outlook Therapeutics established LYTENAVA WAC at $485 per vial in the US.
- Pricing applies to LYTENAVA, the company's ophthalmic product; no patient volumes or revenue disclosed.
- WAC is the base wholesale list price; may affect reimbursement and distribution economics.
- No guidance, clinical data, or launch-date details included in the filing.

## SEC filing metadata
- accession: 0001104659-26-108952
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2026-09-18T20:30:44+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465926108952/0001104659-26-108952-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465926108952/tm2625694d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-108952
- JSON: https://secwatch.observer/filing/0001104659-26-108952.json
- Plain text: https://secwatch.observer/filing/0001104659-26-108952.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.